Canada's Aurinia Pharmaceuticals Inc. added Michael Hayden to its board.
Hayden most recently served as president of global research and development and chief scientific officer at Teva Pharmaceutical Industries Ltd.
Aurinia Pharmaceuticals appoints director
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Canada's Aurinia Pharmaceuticals Inc. added Michael Hayden to its board.
Hayden most recently served as president of global research and development and chief scientific officer at Teva Pharmaceutical Industries Ltd.